2.84
1.73%
-0.05
Revance Therapeutics Inc stock is currently priced at $2.84, with a 24-hour trading volume of 1.93M.
It has seen a -1.73% decreased in the last 24 hours and a -21.33% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.87 pivot point. If it approaches the $2.79 support level, significant changes may occur.
Previous Close:
$2.89
Open:
$2.89
24h Volume:
1.93M
Market Cap:
$296.63M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
-0.6269
EPS:
-4.53
Net Cash Flow:
$-223.46M
1W Performance:
+4.80%
1M Performance:
-21.33%
6M Performance:
-58.05%
1Y Performance:
-90.71%
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
510-742-3400
Address
7555 Gateway Boulevard, Newark, CA
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
Sep-22-22 | Initiated | Goldman | Buy |
Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-15-20 | Reiterated | Needham | Buy |
Aug-11-20 | Resumed | Mizuho | Buy |
Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
Dec-02-19 | Initiated | Goldman | Buy |
Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Jun-11-19 | Initiated | Barclays | Overweight |
Feb-15-19 | Initiated | Wells Fargo | Market Perform |
Feb-14-19 | Initiated | H.C. Wainwright | Buy |
Jan-29-19 | Initiated | Stifel | Buy |
Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Apr-20-18 | Reiterated | Mizuho | Buy |
Mar-27-18 | Initiated | Needham | Buy |
Mar-05-18 | Initiated | Goldman | Buy |
Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
Dec-06-17 | Initiated | Guggenheim | Buy |
Dec-06-17 | Reiterated | Mizuho | Buy |
Nov-27-17 | Initiated | Barclays | Overweight |
Nov-17-17 | Initiated | Mizuho | Buy |
Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Stock Holdings Lessened by Teacher Retirement System of Texas - Defense World
Defense World
Quest Partners LLC Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Defense World
10554 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Purchased by Victory Capital Management Inc. - Defense World
Defense World
Does Revance Therapeutics, Inc.'s (NASDAQ:RVNC) CEO Pay Compare Well With Peers? - Yahoo Movies UK
Yahoo Movies UK
Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings? - Yahoo News UK
Yahoo News UK
Aigen Investment Management LP Acquires Shares of 19569 Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Defense World
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revance Therapeutics Inc (RVNC) Revenue 2024
RVNC reported a revenue (TTM) of $234.04 million for the quarter ending December 31, 2023, a +76.55% rise year-over-year.
Revance Therapeutics Inc (RVNC) Net Income 2024
RVNC net income (TTM) was -$323.92 million for the quarter ending December 31, 2023, a +9.20% increase year-over-year.
Revance Therapeutics Inc (RVNC) Cash Flow 2024
RVNC recorded a free cash flow (TTM) of -$223.46 million for the quarter ending December 31, 2023, a -13.57% decrease year-over-year.
Revance Therapeutics Inc (RVNC) Earnings per Share 2024
RVNC earnings per share (TTM) was -$3.80 for the quarter ending December 31, 2023, a +21.00% growth year-over-year.
About Revance Therapeutics Inc
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Cap:
|
Volume (24h):